Skip to content

Adhera Therapeutics, Inc.

CIK 0000737207

← back to feed
Revenue (TTM)
$117K
+231.6% YoY Q3 Nov 2023
Net Income (TTM)
−$5.95M
+66.7% YoY Q3 Nov 2023
EPS Diluted (TTM)
−$1.68
+72.5% YoY Q3 Nov 2023
Gross Margin
-59.8%
Q3 Nov 2023
Operating Margin
-1,253.0%
Q3 Nov 2023
Net Margin
-5,088.7%
Q3 Nov 2023
Free Cash Flow (TTM)
−$969K
Q3 Nov 2023
Cash
$32K
Q3 Nov 2023
Total Debt
$1.2M
Q3 Nov 2023
Shares Outstanding
7.22M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings